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Abstract-The total content and extent of processing of the +MSH and P-endorphin- 
containing N- and C-terminal domains of proopiomelanocortin were determined in the 
anterior and intermediate lobes of the pituitaries and in 11 regions of the brains of three 
Rhesus monkeys. Most immunoreactive ,3MSH and p-endorphin was located in the pituitary 
lobes, although significant amounts were also found in several brain regions. Sephadex 
column chromatography revealed that ,3MSH immunoreactivity was found primarily as 4K 
and 9K forms; no ,rMSH was detected. P-Endorphin immunoreactivity was found as 
/3-endorphin, P-lipotropin, and as a 5K form which may represent P-endorphin extended 
N-terminally by part or all of P-MSH. In the anterior lobe of the pituitary, the predominant 
products were 9K ,sMSH and P-lipotropin; in the intermediate lobe, more processed forms 
(4K +MSH, P-endorphin and 5K P-endorphin) appeared to be preferentially stored. The 
pattern of processing in various brain regions was similar to that of the intermediate lobe of 
the pituitary. 
Introduction brain. The processing of POMC in various tissues 
Proopiomelanocortin (POMC) is a 31000 dalton has been partially el&idated in multiple species, 
propeptide containing multiple functional 
with emphasis on the PE and ACTH-containing 
domains, including P-endorphin (PE), adreno- 
C-terminal domain; considerably less is known, 
corticotropin (ACTH), and OL-, p-, and y-melano- 
however, about the processing of the y-MSH-con- 
tropins (MSHs). Although the majority of POMC 
taining N-terminal region. Tissue-specific process- 
is found in the pituitary, it has also been found in 
ing of POMC in the monkey has received little 
other sites in lower concentrations, including the 
attention to date; as in other species, the process- 
ing of the N-terminal domain of POMC in primate 
neural tissue is not well understood. PateI-et al. in 
Date received 17 December 1987 our laboratories have recently cloned monkey 
Date accepted 21 December 1987 POMC, however, which should facilitate the 
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investigation of the processing of POMC in this periventricular grey are fully-processed (i.e., 
species based on the actual primary structure. B-endorphin). 
y-Melanotropin (+MSH) is found within the Because of the similarities between human and 
N-terminal domain of POMC, located between monkey POMC, the processing of monkey POMC 
the two major dibasic cleavage sites in the 16K is potentially relevant to human physiology. We 
N-terminal region (18). Within this 16K region, previously reported on the content and partial 
,3MSH is flanked by the extreme N-terminal processing of +MSH and PE in the monkey 
fragment of POMC and by joining peptide. ,3MSH pituitary (16). In this paper, we extend these 
can thus be theoretically found alone (molecular earlier observations, reporting content and com- 
weight 3-4K), in association with joining peptide plete processing of both y-MSH and PE in monkey 
or with the extreme N-terminal fragment of pituitary and in selected brain regions. 
POMC (molecular weight 9-11K) (22, 23), or as 
part of the intact 16 K N-terminal domain. ,xMSH 
shares considerable homology between the human 
and the monkey. The N-terminal region of the 
peptide (residues l-18) are completely conserved 
between the two species, an area that contains a 
potential dibasic cleavage site as well as a glyco- 
sylation signal. The C-terminal region of the 
peptide, however, shows considerable variability 
between the two species, and is only five residues 
in length in the monkey, compared with eight in 
the human (Pate1 et al., in preparation). The 
additional theorectical cleavage site (Arg-Arg, 
positions 13-14) located within +MSH in both the 
human and the monkey potentially yields a 12-resi- 
due peptide (+MSH), or an 11-residue, C- 
amidated peptide, ,,MSH (15). Neither of these 
products, however, have been demonstrated in the 
human pituitary (11,22, 23, 25, 26). 
Past efforts to determine the distribution and 
extent of processing of immunoreactive-y-melano- 
tropin in primate neural tissue have focused on the 
pituitary. y-MSH has been found primarily as 
larger molecular forms (i.e., 9 K or larger) in the 
human pituitary (4, 22, 23, 25). The distribution 
and extent of processing y-melanotropin and PE in 
the primate brain have been rarely reported. 
Osamura and colleagues (19) studied y-MSH in 
the human hypothalamus by immunocytochemistry 
and found that it tended to be colocalized with PE, 
and located primarily in the arcuate nucleus; these 
investigators also performed electron microscopic 
studies in this tissue, finding y-MSH localized in 
nerve terminals and in synapse-like structures, 
suggesting a possible neuromodulatory role for 
this peptide. Emson et al. (10) quantitated some 
POMC products, including PE but not y-MSH, in 
human brain, finding relatively increased amounts 
in the hypothalamus, amygdala, periventricular 
grey, substantia nigra, and the superior colliculus. 
Column chromatography revealed that the pri- 
mary peptide forms in the hypothalamus and 
Methods 
Tissue preparation. Three post-menopausal Rhe- 
sus monkeys (Macaca mulatta) were anesthetized 
with pentobarbital and sacrificed by exsangui- 
nation. The brain and pituitary were rapidly 
removed and kept on wet ice for dissection. The 
pituitary was dissected into anterior and inter- 
mediate lobes. Due to the adhesion of the inter- 
mediate lobe to the other lobes, this tissue was 
somewhat contaminated by both anterior and 
posterior lobe tissue, hence, in this study, “inter- 
mediate” lobe actually refers to a mixture of all 
three pituitary lobes, although predominately 
intermediate lobe. The brain was dissected on wet 
ice into the following regions: hypothalamus, 
hippocampus, septum, colliculi, amygdala, stria- 
turn, thalamus, midbrain, pons, medulla, and 
portions of frontal and occipital cortex. Immedi- 
ately following dissection, individual tissue 
sections were frozen on dry ice and stored at 
-80°C. 
Prior to extraction, individual tissue sections 
were weighed. Extraction was accomplished by 
subjecting tissue in 2ml acetone/O.1 N HCl (3:1, 
v/v) to a Polytron for 6Os, followed by a 1 ml rinse 
in acetone/HCl. The homogenate was centrifuged 
at 12OOOXg for 10 min and the supernatant 
collected and lyophilized. The dried extract was 
resuspended in 1 ml 1.0% formic acid. 
Radioimmunoassays. PE was assayed by a pre- 
viously validated radioimmunoassay (1, 6). The 
antiserum is directed against a midportion of the 
PE molecule (residues 17-27), and is 100% cross- 
reactive with all forms of SE, P-lipotropin, and 
POMC. +MSH was assayed using a radioimmuno- 
assay that we have previously standardized (16,17, 
27). This antiserum is directed against a mid- 
portion region of bovine +MSH (residues 5-14), 
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which shares complete homology with both 
monkey and human ,sMSH. This antisera does not 
cross-react with ,iMSH or +MSH. 
,iMSH was quantitated by a recently developed 
radioimmunoassay. The antiserum was raised in 
rabbits against synthetic ,iMSH (monkey, human, 
and bovine sequences are identical) conjugated to 
thyroglobulin. The assay was performed in 
150mM phosphate buffer, pH 8.2, containing 
0.1% bovine serum albumin and 1.0% NaCl. 
Standards (synthetic Lys-,iMSH) and samples 
were added in 5OuL of 0.1% bovine serum albu- 
min, pH 3.0. The antiserum was added in 1OOuL of 
buffer at a final titer of 1:3000. Due to difficulties 
of [i*‘I] ,iMSH instability in this assay, the radio- 
ligand was rat [125I] Lys-,jMSH which was iodi- 
nated by the chloramine-T method (13); 20000 
counts in 1OOuL of buffer containing 5% rabbit 
serum were added per tube. The assay was run in 
triplicate in a final volume of 25OuL under disequi- 
librium conditions for 48-72h at 4°C. Separation 
was by immunoprecipation following the addition 
of 15uL of sheep-anti-rabbit IgG. This assay 
typically has an ICsO of 60 fmoles ,iMSWtube, and 
a sensitivity of 5 fmoles/tube. The antiserum has 
57% cross-reactivity with synthetic human ,xMSH, 
2% with ACTH1_23, and <O.l% with CX-MSH, 
B-MSH and BE. The intra- and inter-assay coeffi- 
cients of variation are 5.3% and 8.4%, respec- 
tively. 
Peptide measurement paradigm. Aliquots of 
extracted tissue were lyophilized, resuspended in 
the appropriate solvent, and assayed for ,sMSH 
and BE immunoreactivity. From those regions 
with sufficiently high concentrations of peptides 
(both pituitary lobes, hypothalamus, pons, 
septum, and colliculi), aliquots (300-4OOuL) were 
chromatographed on a Sephadex G-50 column 
(0.9 x 90cm). The column was developed in 1.0% 
formic acid, and 2.2ml fractions collected. Indivi- 
dual fractions were lyophilized, and resuspended 
in the appropriate solvent for PE, ,sMSH and 
,iMSH quantitation by radioimmunoassay. Ali- 
quots of fractions contituting the void volumn 
from this column were pooled, lyophilized. resus- 
pended in 300 uL of 1 .O% formic acid, and rechro- 
matographed on a Sephadex G-100 column (0.9 X 
9Ocm) in 1 .O% formic acid to better resolve larger 
molecular weight forms. The total amount of BE, 
Y3MSH and ,iMSH found in each observed peak 
from these two columns was calculated, and 
expressed as a percentage of the total immuno- 
reactivity for that peptide for each region exam- 
ined. Recovery of all peptides from the Sephadex 
columns exceeded 90%. 
Concavalin A afinity chromatography. Fractions 
from Sephadex G-50 columns corresponding to a 
4000 dalton form of ,sMSH from the pituitary were 
pooled and applied to a Concanavalin A-Sepha- 
rose 4B affinity column. This method has been 
used previously to demonstrate that bovine (24) 
and human (17) ,3MSH is glycosylated. Briefly, 
samples were resuspended in 5OOuL of buffer and 
applied to a 5OOuL affinity column. Following 
extensive washing, glycosylated material was 
eluted by increasing concentrations of cr-methyl- 
D-mannopyranoside and by acetic acid. 1 ml frac- 
tions were collected from this column and lyophi- 
lized. +MSH content was determined in each 
fraction by radioimmunoassay. 
Results 
Peptide content. The total amount of ,jMSH and 
BE immunoreactivity found in the individual brain 
and pituitary regions is summarized in Table 1. 
Both ,xMSH and PE were found concentrated in 
the two pituitary lobes, although significant levels 
were also detected in the hypothalamus, colliculi, 
septum and pons. Lower levels were detected in 
the remaining brain regions. There was no signifi- 
cant difference between total immunoreactive 
(IR)-PE and IR-,sMSH in any given tissue. 
Inspection of Table 1 reveals fairly large standard 
errors, partially due to the small number of 
animals studied. 
Processing of y-MSH in brain and pituitary 
regions. The percentage of ,sMSH immunoreac- 
tivity found as fragments of various molecular 
weights was calculated from Sephadex column 
chromatography, and is summarized in Table 2. 
As shown in the representative elution profiles of 
y-MSH in the “intermediate” and anterior lobes of 
the pituitary in the top panels of Figures 1 and 2, 
IR-.,aMSH was found in peaks of 4K. 9K, 16K 
(POMC N-terminal to ACTH), and in the void 
volume (presumably intact POMC). In all studied 
tissues, most IR-+MSH was found as 4K and 9K 
forms. In the anterior lobe of the pituitary (Fig 2), 
the predominant form was 9 K. In “intermediate” 
lobe (Fig 1) and the various brain regions, how- 
ever, the 4K form either predominated or was 
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nearly equal to the amount of 9 K ,sMSH. In spite 
of the obvious extent of processing of ,sMSH to 4 K 
and 9K forms in all tissues, a significant amount 
(up to 25%) of +MSH immunoreactivity was 
found as the 16K form..,iMSH was not found in 
any of the tissues listed m Table 2. 
Processing of @LT. As a comparison control, the 
extent of processing of PE immunoreactivity was 
determined in parallel with ,aMSH. These results 
are summarized in Table 3. As shown in represent- 
ative elution profiles (lower panels, Figs 1 and 2), 
BE immunoreactivity was found as BE, B-lipo- 
tropin, and a larger form (presumably POMC). 
Additionally, some was found as a 5 K form, which 
is presumably BE extended to N-terminally by 
part or all of B-MSH. In anterior pituitary (Fig 2), 
62% of IR-BE was found to exist as B-lipotropin; 
in contrast, in “intermediate” lobe (Fig 1) and the 
various brain regions, most was found as the 
smaller, more processed forms (BE and the 5K 
form). 
Table 1 B-Endorphin and ,JMSH Content in Various Monkey Brain and Pituitary Regions 
Region 
Pituitary, anterior lobe 












Peptide content (fmoleslmg) 
IR-,MSH 
120400 zk 33000 
68500 + 19800 
25.2 + 21.2 
10.6 + 4.5 
1.4 + 3.2 
5.2 * 5.0 
2.5 + 2.2 
1.9 +_ 0.6 
1.1 + 0.9 
1.0 f 0.4 
0.9 +_ 0.6 
0.4 -t 0.2 
0.2 + 0.2 
IR-PE 
91200 f 25000 
97 500 + 45 600 
49.9 + 44.1 
8.1 f 4.0 
3.3 f 3.1 
7.0 i 4.1 
4.1 ? 4.1 
11.3 * 8.9 
2.0 f 0.8 
2.6 + 1.7 
3.1 + 1.5 
I.8 +_ 1.5 
0.4 * 0.4 
* “intermediate” lobes contain small amounts of both anterior and posterior lobes well. as described in the text. 
_ Results are means + S.E.M. of values from three animals. 
Table 2 Distribution of Immunoreactive +MSH by Molecular Weight as Determined by Sephadex Column 
Chromatography 
% IR-,MSH 
Region 4K 9K 16K Void 
Pituitary, anterior lobe 22% 60% 18% 1% 
Pituitary, “intermediate” lobe 48 35 16 1 
Hypothalamus 40 34 25 0 
Pons 38 48 13 1 
Colliculi 44 49 7 0 
Septum 50 36 10 4 
4 K presumably represents glycosylated ,sMSH; 9 K, -,s MSH extended with the extreme N-terminal fragment of POMC; 16K. the 
N-terminal region of POMC less ACTH and f3-lipotropin; void, intact POMC. “Intermediate” lobes are contaminated by small 
amounts of anterior and posterior lobes, as discussed in the text. 
Table 3 Distribution of Immunoreactive (GEndorphin by Molecular Weight 
% IR-P-endorphin 
Region PE 5K f3-lipotropin 
Pituitary, anterior lobe 21% 16% 62% 
Pituitary, “intermediate” lobe 31 42 20 
Hypothalamus 28 44 22 
Pons 6 56 36 







Septum 46 15 35 4 
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Fig I Representative elution profiles of y-MSH and f3E 
immunoreactivity from a Sephadex G-50 column. The two 
profiles represent parallel determinations of y-MSH (top 
panel) and f3E (lower panel) in the “intermediate” lobe of the 
pituitary. The void volume peak from the y-MSH determin- 
ation was pooled and re-chromatographed on Sephadex G-100 
(insert, top panel). as described in the text. 
Extent of Glycosylation of ,MSH. A representa- 
tive profile of pituitary-derived 4K ,3MSH from a 
Concanavalin A affinity column is shown in Figure 
3. Similar to findings in human plasma (17) and 
bovine pituitary (24), most (76 5 10%) of this 
material is glycosylated. As a control, less than 
10% of synthetic, nonglycosylated, human +MSH 
is retained by these affinity columns. 
Discussion 
The largest concentrations of +MSH and PE were 
found in the anterior and “intermediate” lobes of 
the pituitary, although significant amounts were 
also found in the hypothalamus, pons, septal 
region, and colliculi. This is in agreement with 
previous reports of substantial amounts of ?I-MSH 
in the human pituitary (4, 22, 23, 25). Although 
the distribution of ?I-MSH has not been deter- 
mined in the primate brain, it has been studied in 
the rat brain immunohistochemically (5, 14). 
These studies have demonstrated that y-MSH 
parallels the distribution of PE; y-MSH ceh bodies 
are localized in the intermediate lobe of the 
pituitary, corticotrophs in the anterior lobe, and 
the arcuate nucleus. Kawai et al. (14) also demon- 
strated a collection of y-MSH-containing neurons 
in the nucleus commissuralis. y-MSH-immuno- 
reactive nerve fibers have been demonstrated 
within the diencephalon, pons, hypothalamus, 
amygdala, and the central grey of the midbrain. 
Several other investigators have studied the 
distribution of other POMC products in brain. 
although ?I-MSH itself was not explored. DuPont 
and co-workers (8) quantitated gE in bovine and 
rat brain, finding the largest concentration in the 
hypothalamus of both species, followed by the 
periaqueductal grey. thalamus and amygdala in 
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Fig 2 Parallel determinations of y-MSH (top panel) and f3E 
(lower panel) immunoreactivities in the anterior lobe of the 






Fig 3 Representative elution profile of ,*MSH immunoreac- 
tivity in pituitary from a Concanavahn A-Sepharose 4B affinity 
column. Aliquots of fractions comprising the 4K +MSH peak 
were pooled and chromatographed on the affinity column. 
Glycosylated material was eluted with increasing concentration 
of a-methyl-D-mannopyranoside (aMM) and 0.1 N acetic acid. 
the rat, and by the pons and septum in bovine 
tissue. Multiple POMC products, including PE, 
ACTH, and a-MSH were studied in the human 
brain (lo), with significant amounts found in the 
hypothalamus, amygdala, periventricular grey, 
substantia nigra, and superior colliculus. The 
distribution of ,aMSH and PE in the monkey 
agrees well with these studies in other species; the 
largest amounts of immunoreactivity are found in 
tissues rich with POMC-containing neurons (pitui- 
tary and hypothalamus), and relatively less pep- 
tide is found in tissues associated with fiber tracts, 
The processing of y-MSH in the monkey pitu- 
itary appears to be similar to the processing in 
other species. For example, ?I-MSH is processed to 
a smaller form (glycosylated ,sMSH), and is also 
found as a larger form (lo-11 K) in rat (20) and 
bovine pituitaries (24). In both species, the smaller 
form predominates in the intermediate lobe, 
whereas the somewhat larger form is preferentially 
stored in the anterior lobe, in agreement with our 
results in the monkey. y-MSH has also been 
studied in the human pituitary. Only a larger form 
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of ?I-MSH-immunoreactivity is found, however 
(22, 23, 25), which in the human corresponds to 
+MSH extended with the extreme N-terminal 
fragment of POMC (22,23). Based on findings in 
other species, 9 K ,3MSH is likely ,sMSH extended 
with the extreme N-terminal fragment of POMC, 
although it is possible that 9K form in monkey is 
+MSH extended by joining peptide. It is of note 
that in the anterior lobe of the monkey, some of 
this intermediate-sized product is further pro- 
cessed to 4K .xMSH, a processing step that does 
not appear to occur in human pituitary tissue. 4K 
.sMSH is likely glycosylated ,sMSH, as found in 
other species. Because of slight differences in the 
primary structure of monkey POMC compared to 
that of rat and human, the identification of the 4K 
and 9 K fragments is tentative. While there are two 
minor amino acid differences between the human 
and monkey sequences of the extreme N-terminal 
fragment of POMC, differences in joining peptide 
are more substantial. In monkey joining peptide, 
positions 11-12 are Arg-Gly, compared to Cys-Gly 
in the human (and absent in the rat), resulting in an 
additional possible single basic cleavage site. 4K 
,sMSH in the monkey, then, could conceivably 
also be deglycosylated ,jMSH extended C-termi- 
nally by the first eleven residues of joining peptide. 
PE is processed similarly to y-MSH in the 
monkey pituitary; the “intermediate” lobe tends 
to store more processed forms of BE (PE and a 5 K 
form), and the anterior lobe @lipotropin. Of 
interest is that the anterior lobe is able to further 
process B-lipotropin to smaller forms in significant 
amounts, in agreement with a previous report (7). 
An unexpected finding is the 5 K-sized form of BE. 
This fragment contains BE, and is presumably 
extended N-terminally by some or all of B-MSH. 
This may represent an alternate processing path- 
way for l3E in some tissues in the monkey. 
The processing of y-MSH and PE in various 
brain regions was similar to that in the intermedi- 
ate lobe of the pituitary, with the primary products 
identified as a mixture of the most processed form 
and the immediate precursor to this product for 
both peptides (+MSH and the 9K form, and l3E 
and the 5K form). There have been few reports 
detailing the processing of ,xMSH in brain regions. 
Emeson and Eipper (9) demonstrated that the 
majority of y-MSH in rat hypothalamus is glyco- 
sylated +MSH. Although v-MSH was not studied, 
Emson et al (10) demonstrated that the majority of 
l3E immunoreactivity in the human hypothalamus 
and periventricular grey is BE-sized. The finding in 
monkey brain of substantial processing of POMC 
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to +MSH and PE agrees well with these two 
reports in other species. 
These results in the monkey agree fairly well 
with the limited y-MSH processing data published 
for other species. Several notable differences. 
however, are apparent from our data. In the 
human pituitary, y-MSH processing appears to 
stop at the 9K form, and no smaller forms are 
found. In the monkey, however, significant 
amounts of glycosylated ,jMSH are found, indica- 
ting an additional processing step absent in the 
human. A second unexpected finding was the 
processing of IR-PE to a 5K form; as previously 
mentioned, this may represent an alternate pro- 
cessing route for the C-terminal domain of POMC 
in the monkey. Although r-MSH has a peripheral 
role potentiating ACTH-induced adrenocortical 
steroidgenesis (2,3, 12, 21), its role in the central 
nervous system is unknown. It has been demon- 
strated by electron microscopic studies (19) to 
exist in nerve terminals and synapse-like struc- 
tures. It exists in processed forms in various brain 
regions, as we and others have demonstrated. 
These data suggest that y-MSH may have a 
neuromodulatory role in the central nervous 
system. 
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